Tim Osborne
Vermögen: 252 132 $ am 31.05.2026
Vermögen: 252 132 $ am 31.05.2026
Tim Osborne currently works at Forward Air Corp., as Executive Vice President-Operations from 2024.
Dr. Osborne also formerly worked at the University of California, Irvine, as Principal and Select BioVentures LLC, as Advisor.
Dr. Osborne received his undergraduate degree from King University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
FORWARD AIR CORPORATION 0,08 % | 15.03.2026 | 23 831 ( 0,08 % ) | 252 132 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| FORWARD AIR CORPORATION | Geschäftsführer | 01.01.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Select BioVentures LLC
Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Private Equity Investor | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Forward Air Corp.
Forward Air Corp. TruckingTransportation Provides less-than-truckload, final mile, truckload and intermodal drayage services | Transportation |
King University
King University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select BioVentures LLC
Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Finance |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen